NCT04405986

Brief Summary

Although direct evidence is currently lacking, the high identity between SARS-CoV-1 and SARS-CoV-2 suggests, that the latter viral strain could also infect the Central Nervous System (CNS). Indeed, some cases of SARS-COV2 encephalitis begin to be described and CNS damages are increasingly highlighted in the literature, but still not objectified by imaging and do not allow to explain the entire clinical patterns. We hypothesise that these CNS damages are not always objectified by Magnetic Resonance Imaging (MRI) but could be indirectly observed by a physiological dysfunction of neural conduction in the brainstem. We will explore brainstem disruption through an electrophysiological approach.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
38

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started May 2020

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 8, 2020

Completed
11 days until next milestone

Study Start

First participant enrolled

May 19, 2020

Completed
9 days until next milestone

First Posted

Study publicly available on registry

May 28, 2020

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 10, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 10, 2021

Completed
Last Updated

April 8, 2021

Status Verified

April 1, 2021

Enrollment Period

10 months

First QC Date

May 8, 2020

Last Update Submit

April 7, 2021

Conditions

Keywords

COVID-19BrainstemElectrophysiology

Outcome Measures

Primary Outcomes (5)

  • Latency of electrophysiological response

    Latencies of electrophysiological responses with Auditory Evoked Potentials

    Inclusion (T0)

  • Delay of Muscle contraction

    Delay of Muscle contraction (Blink reflex)

    Inclusion (T0)

  • Delay of silent period

    Delay of silent period while the patient is asked to tighten the jaws (Masseter Inhibitory Reflex)

    Inclusion (T0)

  • Duration of silent period

    Duration of silent period while the patient is asked to tighten the jaws (Masseter Inhibitory Reflex)

    Inclusion (T0)

  • Inhibition rate

    Inhibition rate while the patient is asked to tighten the jaws (Masseter Inhibitory Reflex)

    Inclusion (T0)

Study Arms (1)

Electrophysiological procedure

EXPERIMENTAL

Brainstem reflexes and neural conduction will be explored using Auditory Evoked Potentials (AEP) and blink and Masseter Inhibitory Reflex (MIR) in hospitalised patients with COVID infection

Procedure: Auditory Evoked Potentials (AEP)Procedure: Blink and Masseter Inhibitory Reflex

Interventions

Record of electrophysiological responses (Auditory Evoked Potentials or AEP) during auditory stimulations with an electroencephalogram (EEG).

Electrophysiological procedure

Electrophysiological exploration while stimulating trigeminal nerve to record 1) motor response induced (muscle contraction delay (Blink)) of the facial nerve, or 2) the contraction inhibition of masseters (Masseter Inhibitory Reflex (MIR)).

Electrophysiological procedure

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18 years.
  • Hospitalized patient suffering from a positive COVID 19 diagnosed by Reverse transcription polymerase chain reaction (RT-PCR) or chest computed tomography scan (CTscan) with specific lesions

You may not qualify if:

  • History of neurological damage interfering with auditory evoked potentials (PEA) and Electromyography (EMG) reflexes of the brainstem (stroke of the brainstem, acoustic neuroma, amyotrophic lateral sclerosis, facial diplegia, damage to nerves V or VII, etc.)
  • Impaired alertness
  • Sedative treatments or treatments that disturb nerve conduction.
  • Pregnancy or breastfeeding
  • Individuals under legal protection or unable to express personally their consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU de Bordeaux

Bordeaux, 33 076, France

Location

MeSH Terms

Conditions

COVID-19

Interventions

Evoked Potentials, AuditoryBlinking

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Evoked PotentialsCortical ExcitabilityElectrophysiological PhenomenaPhysiological PhenomenaVestibulocochlear Physiological PhenomenaNervous System Physiological PhenomenaMusculoskeletal and Neural Physiological PhenomenaReflexOcular Physiological Phenomena

Study Officials

  • Bertrand Glize

    bertrand.glize@chu-bordeaux.fr

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 8, 2020

First Posted

May 28, 2020

Study Start

May 19, 2020

Primary Completion

March 10, 2021

Study Completion

March 10, 2021

Last Updated

April 8, 2021

Record last verified: 2021-04

Locations